AUTHORED BY
Maria DeBono
Thomas Bugeja
Nikol Caruana
READING TIME
< 1 MINS
Practice Area
Corporate Law
In the first part of the fourth episode of the Law Booth, Maria DeBono, an Associate within the Corporate & Commercial department at the firm, discusses Subsidiary Legislation 386.24 titled the “Companies Act (Suspension of Filing for Dissolution and Winding Up) Regulations” (the “Regulations”) with Senior Associate Thomas Bugeja and Associate Nikol Caruana, both also working within the same department at the Firm, to provide our listeners with an introduction to the Regulations and what they entail. In the second part of the episode, Maria is joined by none other than the Official Receiver within the Malta Business Registry, Dr. Kevan Azzopardi who sits down to answer some of our pressing questions regarding the Regulations and how these have played out in practice.
Listen to the podcast here: shorturl.at/vKTY6
OUTLINE
Related Insights
Malta Chapter for White & Case’s 2025 Foreign Direct Investment Reviews Guide
View
Challenging Enforcement of Cross-Border Tax Claims under Council Directive 2010/24/EU
View
The Significance of the Register of Members in Corporate Practice: Overlooked yet Essential
View
Bill 96 – Share Buy-Backs and Reduction of Share Capital: The Proposed Amendments
View
Time to repeal the Suspension of Filing for Dissolution and Winding up Regulations
View
Redom Updated – Cross-Border Conversion of Limited Liability Companies (Part 2 of 3)
View
Malta’s foreign direct investment (FDI) regime and its implications in practice
View
The Corporate Sustainability Reporting Directive (CSRD) finally comes into force
View
The meetings of a Maltese company: How critical is the company secretary’s role?
View
Farmers, fishermen and primary food suppliers to benefit from protection against unfair trade practices
View
Is it time to ‘wind up’ the suspension of filing for dissolution and winding up regulations?
View
Re-Dom Alert: Continuation of a Maltese Company outside Malta – Part 2 of 2
View
EU merger control toughens up on Pharma and Digital deals with the EC’s new Article 22 Guidance on referrals to the EC
View
